Search research articles
Contact Us
Filters
Showing results (31-40 of 37) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 37 results.
Nanoscale
|
August 17, 2016
Carbon-based molecular devices: Fano effects controlled by the molecule length and the gate voltage
X F Yang, Y W Kuang, Y S Liu, et al.
Zhonghua Yi Xue Za Zhi
|
August 15, 2020
[Phase Ⅲ randomized controlled, multicenter, prospective study of recombinant anti-HER2 humanized monoclonal antibody (Cipterbin) combined with vinorelbine in patients with HER2 positive metastatic breast cancer: the HOPES Study]
L Bian, B H Xu, L J Di, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|
November 18, 2021
[Correlation between nUGT1A1 gene polymorphisms and adverse events of irinotecan plus S-1 for patients with recurrent or metastatic esophageal squamous cell carcinoma: a prospective, open-label, randomized controlled trial (ESWN 01)]
X Wang, Y Liu, J X Huang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 10, 2015
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
M Schuler, J C-H Yang, K Park, et al.
Nature Communications
|
September 8, 2017
Tunneling anisotropic magnetoresistance driven by magnetic phase transition
X Z Chen, J F Feng, Z C Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 26, 2019
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
F Wang, X L Wei, F H Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 26, 2017
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study
Y K Shi, L Wang, B H Han, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 37) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 37 results.
Nanoscale
|
August 17, 2016
Carbon-based molecular devices: Fano effects controlled by the molecule length and the gate voltage
X F Yang, Y W Kuang, Y S Liu, et al.
Zhonghua Yi Xue Za Zhi
|
August 15, 2020
[Phase Ⅲ randomized controlled, multicenter, prospective study of recombinant anti-HER2 humanized monoclonal antibody (Cipterbin) combined with vinorelbine in patients with HER2 positive metastatic breast cancer: the HOPES Study]
L Bian, B H Xu, L J Di, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|
November 18, 2021
[Correlation between nUGT1A1 gene polymorphisms and adverse events of irinotecan plus S-1 for patients with recurrent or metastatic esophageal squamous cell carcinoma: a prospective, open-label, randomized controlled trial (ESWN 01)]
X Wang, Y Liu, J X Huang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 10, 2015
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
M Schuler, J C-H Yang, K Park, et al.
Nature Communications
|
September 8, 2017
Tunneling anisotropic magnetoresistance driven by magnetic phase transition
X Z Chen, J F Feng, Z C Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 26, 2019
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
F Wang, X L Wei, F H Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 26, 2017
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study
Y K Shi, L Wang, B H Han, et al.
Page
of 4